Evidence map›Paper›PMID 39305136›Full record

ArticleESC heart failure2025

Importance of non-cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction.

Yasuhiro Hamatani, Moritake Iguchi, Takao Kato, Yasutaka Inuzuka, Yodo Tamaki, Neiko Ozasa, Tetsuma Kawaji, Masahiro Esato, Hikari Tsuji, Hiromichi Wada and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yasuhiro HamataniDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Moritake IguchiDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Takao KatoDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yasutaka InuzukaDepartment of Cardiovascular Medicine, Shiga Medical Center for Adults, Moriyama, Japan.
Yodo TamakiDivision of Cardiology, Tenri Hospital, Tenri, Japan.
Neiko OzasaDivision of Cardiology, Takanohara Central Hospital, Nara, Japan.
Tetsuma KawajiDivision of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan.
Masahiro EsatoDepartment of Arrhythmia, Ogaki Tokushukai Hospital, Ogaki, Japan.
Hikari TsujiTsuji Clinic, Kyoto, Japan.
Hiromichi WadaDivision of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Koji HasegawaDivision of Translational Research, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Mitsuru AbeDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Takeshi KimuraDepartment of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.
Koh OnoDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Masaharu AkaoDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.ORCID https://orcid.org/0000-0002-2348-7646
Fushimi AF Registry and KCHF Registry investigators

Funding

Astellas PharmaAstraZenecaBayer HealthcareBoehringer IngelheimBristol-Myers SquibbDaiichi SankyoJapan Agency for Medical Research and Development 18059186Japan Agency for Medical Research and Development 18ek0210056h0003Japan Agency for Medical Research and Development 19ek0210082h0003MSDNovartis PharmaPfizerSanofi-AventisTakeda Pharmaceutical
6 · The paper itself

Abstract

aimsAtrial fibrillation (AF) and heart failure (HF) with preserved ejection fraction (HFpEF) are interlinked and frequently coexisting conditions. To date, patients with AF and HFpEF have limited evidence guiding their management. This study aimed to investigate the predictors of adverse outcomes among patients with AF and HFpEF.

methodsThe Fushimi AF Registry is a community-based prospective survey of AF patients in Fushimi-ku, Kyoto, Japan. From the registry, we explored predictors for a composite of cardiac death or HF hospitalization among AF patients with HFpEF (defined as having a prior HF hospitalization or New York Heart Association class ≥2 in association with heart disease and left ventricular ejection fraction ≥50%). Besides, we investigated whether the scoring using the predictors identified by the Fushimi AF Registry could stratify the outcomes in patients with AF and HFpEF registered in another independent Kyoto Congestive Heart Failure Registry.

resultsOf 755 patients with AF and HFpEF [mean age: 77.5 ± 9.9 years; female: 391 (52%); paroxysmal AF: 258 (34%); and mean CHA

conclusionsNon-cardiovascular comorbidities such as anaemia, diabetes mellitus and kidney or pulmonary disease in addition to advanced age were independent predictors of adverse outcomes in patients with AF and HFpEF. Our study suggests the importance of focusing on these non-cardiovascular comorbidities for individualized risk stratification and optimal management in patients with AF and HFpEF.

Indexed as

Atrial FibrillationHeart FailureRegistriesStroke VolumeVentricular Function, LeftAgedAged, 80 and overComorbidityFemaleFollow-Up StudiesHospitalizationHumansJapanMalePrognosisProspective Studiesatrial fibrillationcomorbiditiesheart failurepreserved ejection fraction

Identifiers

PMID39305136
PMCPMC11769661

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.